DUBLIN–(BUSINESS WIRE)–The “Global High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma), and Region – Forecast to 2027” report has been added to ResearchAndMarkets.com’s offering.
The global HPAPI market is projected to reach USD 39.6 Billion by 2027 from USD 24.5 billion in 2022, at a CAGR of 10.1% from 2022 to 2027.
The innovative HPAPIs segment is expected to account for the largest share of the market in 2021
Based on type, the HPAPI market is segmented into innovative and generic. The innovative segment is expected to account for the largest share of the HPAPI market in 2021. The large share can be attributed to the increased R&D investments.
The Synthetic APIs segment to account for the largest share of the market in 2021
Based on type of synthesis, the market is segmented into synthetic and biotech HPAPIs. The synthetic APIs segment is expected to command the largest share in 2021. Ease of production and emergence of new molecules and technological advancements in synthesis are driving growth of synthetic HPAPI segment.
The Oncology segment is expected to account for the largest share of the market in 2021
Based on therapeutic application, the market is divided into oncology, hormonal imbalance, glaucoma, and other therapeutic applications. In 2021, Oncology segment is expected to account for the largest share in the market. The launch of new target therapies in addition to technological advancements and growing prevalence of cancer across the globe are driving growth of oncology segment.
Asia is the fastest growing region of HPAPI market from 2022 to 2027
HPAPI market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). Asia to grow at the highest CAGR during the forecast period. High prevalence of chronic diseases, lifestyle diseases, age related diseases and government efforts for encouragement for the adoption of generics are some of the factors driving the growth of the market in Asia.
Market Dynamics
Drivers
- Increasing Demand for Oncology Drugs
- Growing Demand for Antibody-Drug Conjugates
- Increasing Focus of Leading Pharmaceutical Companies on HPAPIs
- Advancements in HPAPI Manufacturing Technologies
- Growing Focus on Precision Medicine
Restraints
- Increasing Requirement of Large Investments for Employee Safety
- Discrepancies in HPAPI Banding Systems
- Rising Number of Uncertainties Associated with Products
- High Risk of Cross-Contamination
Opportunities
- Growing Opportunities for CMOs and CDMOs
- Increasing Opportunities for Companies in Emerging Markets
Challenges
- Need for Appropriate Process Designs
- Constant Evolution of Industry Standards and Technologies
Companies Mentioned
- AbbVie Inc.
- Bayer
- Boehringer-Ingelheim
- Bristol-Myers Squibb Company
- Eli Lily and Company
- F. Hoffmann-La Roche
- Merck & Co. Inc.
- Novartis International AG
- Pfizer Inc.
- Sanofi
- Teva Pharmaceutical Industry Ltd.
- Viatris Inc.
For more information about this report visit https://www.researchandmarkets.com/r/rxn8y1
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900